| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2012: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Outline of Final Research Achievements |
1.Programmed death 1 (PD-1) is a co-inhibitory receptor in the immunoglobulin superfamily, and functions as a negative regulator of the immune system. We immunohistochemically investigated the expression of PD-1 and PD-L1 in breast cancer cells and assessed the correlation between the prognosis and clinicopathological factors. Expression of PD-L1 is associated with poor prognosis in HER2-positive breast cancer. 2.B7-H3 belongs to the B7 superfamily of immune regulatory ligands and plays an importantrole in the adaptive immune response of co-inhibitory/stimulatory factors in regulating T cells.We immunohistochemically investigated the presence of B7-H3 and forkhead box P3 (Foxp3)-positive Tregs in pathological specimens from 90 patients with breast cancer.B7-H3 and Foxp3 can be regarded as
markers of poor prognosis in breast cancer. These expressions were not correlated, suggesting that B7-H3 expression plays an independent role in tumor immune evasion, regardless of Tregs.
|
